Director Shareholding

Cambridge Antibody Tech Group PLC
20 February 2004

                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
John Aston


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above




4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
As in 2 above


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Market purchase of 2,086 shares to be held as "Invested Shares" under
Executive Incentive Plan


7)  Number of shares/amount of
    stock acquired
2,086


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
None


10) Percentage of issued class
None


11) Class of security
Ordinary 10 pence shares


12) Price per share

£4.75



13) Date of transaction
19 February 2004


14) Date company informed
19 February 2004


15) Total holding following this notification
40,801


16) Total percentage holding of issued class following this notification
0.10%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant
20 February 2004


18) Period during which or date on which exercisable
20 February 2007 to 19 February 2010


19) Total amount paid (if any) for grant of the option
Nil


20) Description of shares or debentures involved: class, number
40,410 Ordinary 10 pence shares


21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise
10 pence per share subject to Award


22) Total number of shares or debentures over which options held
    following this notification
135,461 of which:

95,051 are Options under Company Share Option Plan

34,152 are Restricted Share Awards under Executive Incentive Plan

 6,258 are Matching Shares under Executive Incentive Plan


23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions


24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification
Diane Mellett
Date of Notification 20 February 2004



                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
Peter Chambre


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above




4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
As in 2 above


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Market purchase of 11,153 shares to be held as "Invested Shares" under
Executive Incentive Plan


7)  Number of shares/amount of
    stock acquired
11,153


8)  Percentage of issued class
0.027%


9)  Number of shares/amount
    of stock disposed
None


10) Percentage of issued class
None


11) Class of security
Ordinary 10 pence shares


12) Price per share

£4.75



13) Date of transaction
19 February 2004


14) Date company informed
19 February 2004


15) Total holding following this notification
32,775


16) Total percentage holding of issued class following this notification
0.08%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant
20 February 2004


18) Period during which or date on which exercisable
20 February 2007 to 19 February 2010


19) Total amount paid (if any) for grant of the option
Nil


20) Description of shares or debentures involved: class, number
79,847 Ordinary 10 pence shares


21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise
10 pence per share subject to Award


22) Total number of shares or debentures over which options held
    following this notification
286,821 of which:

206,974 are Options under Company Share Option Plan

 46,388 are Restricted Share Awards under Executive Incentive Plan

 33,459 are Matching Shares under Executive Incentive Plan


23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions


24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification
Diane Mellett
Date of Notification 20 February 2004






                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
David Glover


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above




4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
As in 2 above


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Market purchase of 1,043 shares to be held as "Invested Shares" under
Executive Incentive Plan


7)  Number of shares/amount of
    stock acquired
1,043


8)  Percentage of issued class
0.0025%


9)  Number of shares/amount
    of stock disposed
None


10) Percentage of issued class
None


11) Class of security
Ordinary 10 pence shares


12) Price per share

£4.75



13) Date of transaction
19 February 2004


14) Date company informed
19 February 2004


15) Total holding following this notification
14,555


16) Total percentage holding of issued class following this notification
0.036%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant
20 February 2004


18) Period during which or date on which exercisable
20 February 2007 to 19 February 2010


19) Total amount paid (if any) for grant of the option
Nil


20) Description of shares or debentures involved: class, number
21,429 Ordinary 10 pence shares


21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise
10 pence per share subject to Award


22) Total number of shares or debentures over which options held
    following this notification
142,123 of which:

120,694 are Options under Company Share Option Plan

 18,300 are Restricted Share Awards under Executive Incentive Plan

  3,129 are Matching Shares under Executive Incentive Plan


23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions


24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification
Diane Mellett
Date of Notification 20 February 2004






                      This information is provided by RNS
            The company news service from the London Stock Exchange